NRG1 fusion

All
Insights
Investors
Board of Directors
Leadership
Uncategorized
Our Partners
Scientific Advisory Committee
Publications
Newsroom

December 01, 2022

Manuscripts

Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion

Thavaneswaran et al., JCO Precision Oncology 2022

Read More

June 07, 2022

Posters & Oral Presentations

CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions

Presented at 2022 ASCO Annual Meeting

Presenting Author: Daniel R. Carrizosa, MD

Read More

October 14, 2021

Posters & Oral Presentations

Comprehensive genomic profiling reveals novel opportunities for treatment-refractory gastrointestinal cancers

Presented at AGITG 2021

Wei Yen Chan, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney

Read More

April 10, 2021

Press Releases

Elevation Oncology Announces the Presentation of New Preclinical Data in Pancreatic and Cholangiocarcinoma PDX Models on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling Read More

April 10, 2021

Posters & Oral Presentations

Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

Presented at AACR 2021

Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center

Read More

April 06, 2021

Manuscripts

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions

Odintsov et al., Clinical Cancer Research 2021

Read More

Pages: 12